Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2016)

Anika Therapeutics (ANIK) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $48000.0 as the latest value for Q4 2016.

  • On a quarterly basis, Non-Current Deffered Revenue fell 27.27% to $48000.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $48000.0, a 27.27% decrease, with the full-year FY2016 number at $48000.0, down 27.27% from a year prior.
  • Non-Current Deffered Revenue was $48000.0 for Q4 2016 at Anika Therapeutics, down from $59000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.3 million in Q1 2012 to a low of $48000.0 in Q4 2016.
  • A 5-year average of $1.1 million and a median of $79940.5 in 2015 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 97.21% in 2014, then soared 30.74% in 2015.
  • Anika Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2012, then fell by 4.54% to $2.1 million in 2013, then plummeted by 95.04% to $102000.0 in 2014, then plummeted by 35.29% to $66000.0 in 2015, then decreased by 27.27% to $48000.0 in 2016.
  • Per Business Quant, the three most recent readings for ANIK's Non-Current Deffered Revenue are $48000.0 (Q4 2016), $59000.0 (Q3 2016), and $56000.0 (Q2 2016).